Table 1. Vaccine candidate gap analysis.
PHP | Provincial/territorial PHPs for RSV | RSV vaccine candidate in development to address priority |
---|---|---|
1 | Preventing hospitalization and death in infants | Janssen Junior, GSK Maternal and Pediatric, Novavax Maternal, AstraZeneca/Sanofi Pasteura |
2 | Preventing hospitalization and death in high-risk infants | Janssen Juniors, GSK Maternal and Pediatric, Novavax Maternal, AstraZeneca/Sanofi Pasteura |
3 | Preventing infection in children living in remote settings | AstraZeneca/Sanofi Pasteurb |
4 | Preventing hospitalization and death in children | AstraZeneca/Sanofi Pasteura |
5 | Preventing hospitalization and death in older adults | Janssen Senior, GSK Older Adult, Novavax Older Adult, Bavarian Nordica |
Abbreviations: PHP, public health priority; RSV, respiratory syncytial virus
a RSV candidate directly addresses public health priority
b RSV candidate partially addresses public health priority